13F-HR filed by Ally Bridge Group (NY) LLC
Ally Bridge Group (NY) LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 22 holding rows worth $167,825,872.
- Accession
- 0000950123-24-002153
- Filer
- CIK 1822947
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 22 entries on the cover page, a total value of $167,825,872 stated on the cover page (in dollars after the unit check, H1), rows summing to $167,825,872 with VALUE read as dollars as filed, 13F file number 028-20834. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerFan Yu 028-20833
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| JASPER THERAPEUTICS INC | 471871103 | COM | 3,659,255 | $28,871,522 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 35,000 | $13,315,050 | dollars as filed | |
| SOLENO THERAPEUTICS INC | 834203309 | COM | 309,950 | $12,475,488 | dollars as filed | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 489,938 | $11,572,336 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 241,961 | $11,144,724 | dollars as filed | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 141,348 | $10,123,344 | dollars as filed | |
| OLEMA PHARMACEUTICALS INC | 68062P106 | COM | 659,035 | $9,246,261 | dollars as filed | |
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 150,000 | $8,979,000 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 143,479 | $8,664,697 | dollars as filed | |
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 100,862 | $8,027,607 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 274,923 | $7,560,383 | dollars as filed | |
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 357,271 | $6,809,585 | dollars as filed | |
| GERON CORP | 374163103 | COM | 2,971,639 | $6,270,158 | dollars as filed | |
| AMBRX BIOPHARMA INC | 641871108 | COM | 385,383 | $5,487,854 | dollars as filed | |
| AVADEL PHARMACEUTICALS, PLC | 05337M104 | COMMON STOCK-FO | 347,036 | $4,900,148 | dollars as filed | |
| HARPOON THERAPEUTICS INC | 41358P205 | COM | 428,400 | $4,870,908 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 275,773 | $4,059,379 | dollars as filed | |
| PRAXIS PRECISION MEDICINES I | 74006W207 | COM NEW | 70,424 | $1,569,047 | dollars as filed | |
| COMPASS THERAPEUTICS INC | 20454B104 | COM | 834,630 | $1,302,023 | dollars as filed | |
| PROMIS NEUROSCIENCES INC | 74346M406 | COM NEW | 1,066,674 | $1,226,675 | dollars as filed | |
| CONTEXT THERAPEUTICS INC | 21077P108 | COM | 725,951 | $820,325 | dollars as filed | |
| MEDAVAIL HOLDINGS INC COM NEW | 58406B202 | NEW | 117,897 | $529,358 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-24-002153 | this filing | 2024-02-14 | acceptance time not in the bulk data set |